REDWOOD CITY, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatm
ACADIA Pharmaceuticals and Soleno Therapeutics are both conducting late-stage trials for the treatment of Prader-Willi Syndrome. PWS is a rare disease characterized by various physical and development
REDWOOD CITY, Calif., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treat
No, it isn't related to artificial intelligence — although shares of AI-linked chip maker Nvidia Corp. NVDA, +0.16% have surged more than 200% thus far on the year.
In recent years, most reports of assets surging by thousands of percents in relatively short periods come from the crypto market, where various cryptocurrencies – especially smaller altcoins and mem
An analyst changed his price target on the clinical-stage biotech. He added 10% to his level, which caught the market's attention.
The stock market is ending 2023 with outsized gains. Investors are in a cheerful mood, and many speculative stocks to take profits on are soaring right now.

3 Stock Winners That Are Up 500% or More in 2023

07:00am, Thursday, 14'th Dec 2023
2023 proved to be a wild year, as many investors' top-performing stocks quickly swirled down the drain amid higher interest rates and tightened economic conditions. But, against all odds, the market o
This article is an excerpt from the InvestorPlace Digest newsletter. To get news like this delivered straight to your inbox, click here.
Soleno Therapeutics has seen a surge in stock value after positive data from Phase III trials of its Diazoxide Choline Extended-Release tablet for Prader-Willi Syndrome. The data showed improvements i
In a world in constant evolution and growth, more and more companies are needed that are committed to development and research in the health area. These biotech companies are not only doing the job, b
Soleno announced on Tuesday top-line results for its lead therapy candidate. The company said it plans to submit a New Drug Application to the FDA regarding diazoxide choline controlled-release (DCCR)

Soleno Stock Dives After Its Meteoric Rise

01:28pm, Wednesday, 27'th Sep 2023
The biotechnology company had announced positive study results for its DCCR tablets on Tuesday.
Soleno's (SLNO) shares rally as the late-stage study evaluating diazoxide choline for patients with Prader-Willi syndrome meets its primary and secondary endpoints.
Soleno specializes in treating rare metabolic disorders. The company's lead therapy, DCCR, fared well as a treatment for Prader-Willi syndrome.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE